GleamWall
中文EN

KALA KALA BIO, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1479419 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY72.9%
TTM EPS YoY196.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-345.3%
ROA-43.2%
ROIC (approx.)-1,688.4%
Asset turnover—

Leverage & solvency

Liabilities / assets14.5%
Debt / equity0.00x
Current ratio6.88x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.97x
Accruals ratio42.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$0
R&D expense$18.78M$22.09M
SG&A expense$23.63M$18.34M
Operating income-$39.16M-$40.98M
Interest expense$3.28M$5.78M
Income tax$0$0
Net income-$26.98M-$38.51M
EBITDA-$38.84M-$40.72M
EPS (basic)-3.31-10.15
EPS (diluted)-3.31-10.15
Weighted avg. shares (diluted)8.15M3.80M
Balance sheet
Cash & equivalents$7.56M$51.18M
Current assets$9.49M$52.80M
PP&E, net—$749,000
Total assets$9.49M$55.48M
Current liabilities$2.49M$16.96M
Short-term debt—$10.34M
Long-term debt—$20.10M
Total debt—$30.44M
Total liabilities$2.49M$43.15M
Shareholders' equity$7.00M$12.33M
Net debt—-$20.74M
Shares outstanding556,9956.09M
Cash flow statement
Operating cash flow-$31.99M-$29.38M
Investing cash flow-$15,000-$208,000
Financing cash flow-$11.62M$29.88M
Depreciation & amortization$317,000$259,000
Stock-based compensation$7.00M$8.39M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.